CVS Group (LSE:CVSG) is adapting to the biggest regulatory reset in UK veterinary care in years by moving early on the Competition and Markets Authority's (CMA) remedies, while leaning more heavily on its growing Australian business. The FTSE 250 vet group said in March that it was "comfortable" with the CMA's final decision in its veterinary services market investigation, and that it already complied with many of the measures, having published price lists in late 2025 and jointly branded 117 UK practices.
The trading picture has held up through the upheaval. In an update on 23 July 2026, CVS reported unaudited Revenue up 5.9% to £712.8m for the year to 30 June 2026, with like-for-like sales growth of 2.1%, against 0.2% a year earlier, despite a softer UK economy. Adjusted EBITDA of about £141.5m was in line with consensus and up from £134.6m.
Attention now turns to preliminary results, scheduled for 24 September 2026. They arrive against a backdrop of regulatory change, a Leadership transition and a freshly refinanced balance sheet.
Inside a Network of More Than 475 Practices
CVS operates more than 475 veterinary practices across the UK and Australia, including referral hospitals and out-of-hours services. Around that clinical core it runs Laboratories, Crematoria and online pharmacy divisions, giving it revenue streams that support and feed off its practice network. The group employs about 9,000 people, including around 2,500 vets.
That breadth is typical of the consolidators that have reshaped companion-animal care over the past two decades. Scale allows groups to share diagnostics, purchasing and back-office functions across sites, but it has also attracted scrutiny over pricing transparency and how clearly corporate ownership is communicated to pet owners. Under outgoing chief executive Richard Fairman, the company moved to the Main Market of the London Stock Exchange alongside its inclusion in the FTSE 250.
What the CMA's Final Decision Means for the Business
The CMA published its final decision on 24 March 2026. It introduced no new remedies beyond those in its provisional decision, although it raised the proposed cap on prescription fees to £21 including VAT for the first drug, plus £12.50 for each additional drug. CVS said it believed the remedies were workable, while arguing that some were not fully justified.
The prescription fee cap is significant because written prescriptions let owners buy medicines elsewhere, including online. A capped fee limits one income line for practices, but it may also encourage more owners to shop around for medication, an area where CVS has its own online pharmacy. Publishing price lists and clearer branding aim to make it easier for customers to compare providers.
The remedies are not yet legally binding. A CMA Final Order, expected later in 2026, will bring them into force. Alongside its March response, CVS said it expected to trade in line with market expectations, and the July update was consistent with that.
Australia Becomes a Bigger Growth Engine
The Australian Business is becoming more important to the group's numbers. Revenue there rose to £79.1m from £52.1m, representing around 11% of group revenue and about 16% of EBITDA before central costs. During the year CVS completed six Australian practice acquisitions covering 14 sites, plus a minority buy-out, for a combined A$91.0m (£45.6m), taking its Australian estate to 35 practices across 57 sites.
Group adjusted EBITDA Margin came in at 19.9%, within the company's 19% to 23% guidance range. Capital Expenditure was £36.4m, or roughly 5% of revenue, and CVS expects ongoing capex of about £30m, suggesting a lighter Investment load ahead.
Refinancing, Buyback and a Change at the Top
In May, CVS refinanced £350m of bank facilities, comprising a £125m term Loan and a £225m revolving Credit Facility running to 20 May 2030, plus a £5m overdraft. The margin fell by 20 basis points and the eight-bank syndicate includes Westpac, a lender with an Australian footprint. The company committed to Leverage of no more than 2.0x and, in the same announcement, launched a £50m share buyback and disclosed the purchase of another small-animal practice in New South Wales.
Leadership is also shifting. On 30 March, CVS announced that Richard Fairman, who joined as CFO in 2018 and became CEO in 2019, would retire for personal reasons. He will remain until a successor is appointed, and a search is underway. The company said EBITDA had nearly tripled during his tenure. Chair David Wilton and CFO Robin Alfonso complete the senior line-up.
Risks That Could Shape the Next Chapter
Regulation remains the most visible risk. Until the Final Order is issued, the precise compliance requirements, and their effect on pricing and margins, cannot be fully assessed. Any lingering public scrutiny of vet pricing could also influence customer behaviour and reputation across the sector.
The UK consumer backdrop is another factor. CVS has already referred to a softer UK economy, and pet owners facing tighter budgets may delay non-urgent treatments. In Australia, integrating a rapidly enlarged estate brings execution risk, and a growing overseas contribution adds exposure to currency movements when results are reported in sterling.
Finally, the leadership transition adds uncertainty during a period of regulatory change. Balancing acquisitions, the buyback and the 2.0x leverage commitment will require discipline if trading softens.
What to Watch at the Preliminary Results
The 24 September preliminary results will provide audited figures to compare with the unaudited trading update, along with any commentary on the year ahead. Investors and analysts are likely to look for detail on how CMA compliance is affecting pricing and costs, as well as progress on the buyback and further Australian deals.
Beyond the results, the key milestones are the CMA's Final Order later in 2026 and the appointment of a new chief executive, for which no date has been given.
The Bottom Line
CVS Group (LSE:CVSG) enters its results with revenue growth, an EBITDA margin within its guided range and an increasingly meaningful Australian arm. Its early work on price transparency and branding suggests it has been preparing for the CMA regime rather than reacting to it. How smoothly it absorbs the final remedies, completes the leadership handover and manages growth abroad will shape the next stage for this FTSE 250 vet group.






Please wait processing your request...